Trial Profile
A Phase 1/2 Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Jul 2022
Price :
$35
*
At a glance
- Drugs Adegramotide/nelatimotide (Primary)
- Indications Diffuse intrinsic pontine glioma; Glioblastoma; Glioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sumitomo Pharma
- 07 Jun 2020 Status changed from active, no longer recruiting to completed.
- 07 Mar 2019 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 07 Mar 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.